Maravai Lifesciences Holdings Inc Revenue Growth Rates (MRVI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Maravai Lifesciences Holdings Inc   (NASDAQ: MRVI)
 

MRVI's Revenue Growth by Quarter and Year

Maravai Lifesciences Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRVI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 51.44
1st Quarter March 65.70
FY 117.14

MRVIs Annual Revenue
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2025 $ 184.99 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2024 $ 259.19 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2023 $ 288.95 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2022 $ 883.00 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2021 $ 799.24 millions




MRVI Revenue second quarter 2026 Y/Y Growth Comment
Maravai Lifesciences Holdings Inc reported Revenue growth of 8.53% year on year in the second quarter 2026, to $ 51.44 millions, this is lower than Maravai Lifesciences Holdings Inc 's recent average Revenue improvement of 23.2%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Revenue growth. While Maravai Lifesciences Holdings Inc ' s Revenue increase of 8.53% ranks overall at the positon no. 1877 in the second quarter 2026.


MRVI Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -11.2 % -23.91 % -63.78 %
3rd Quarter September - -37.64 % -2.5 % -65.04 %
2nd Quarter June 8.53 % -35.42 % 6.52 % -71.61 %
1st Quarter March 40.23 % -27 % -18.79 % -67.65 %
FY   - -28.62 % -10.3 % -

Financial Statements
Maravai Lifesciences Holdings Inc 's second quarter 2026 Revenue $ 51.44 millions MRVI's Income Statement
Maravai Lifesciences Holdings Inc 's second quarter 2025 Revenue $ 47.40 millions Quarterly MRVI's Income Statement


MRVI Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 23.19 % -13.48 % 10.87 %
3rd Quarter September - -14.22 % -11.17 % -2.96 %
2nd Quarter June -21.7 % 1.17 % 14.37 % -12.81 %
1st Quarter March 31.16 % -16.95 % -13.43 % -61.39 %
FY (Year on Year)   - -28.62 % -10.3 % -


Back to MRVI Growth rate Comparisons >> Back to MRVI Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #287
Overall #1877

Revenue Y/Y Growth Statistics
High Average Low
364.29 % 23.2 % -71.61 %
(Dec 31 2022)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #287
Overall #1877
Revenue Y/Y Growth Statistics
High Average Low
364.29 % 23.2 % -71.61 %
(Dec 31 2022)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Maravai Lifesciences Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
87.31 % 3.97 % -61.4 %
(Sep 30 2020)  


MRVI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Maravai Lifesciences Holdings Inc disclosed fall in Revenue from the first quarter by -21.7% to $ 51.44 millions, from $ 65.70 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Revenue quarter on quarter growth. While Maravai Lifesciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 3288.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #160
Healthcare Sector #455
Overall #3288
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #160
Healthcare Sector #455
Overall #3288
Revenue Q/Q Growth Statistics
High Average Low
87.31 % 3.97 % -61.4 %
(Sep 30 2020)  


MRVI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Maravai Lifesciences Holdings Inc disclosed fall in Revenue from the first quarter by -21.7% to $ 51.44 millions, from $ 65.70 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Revenue quarter on quarter growth. While Maravai Lifesciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 3288.


Maravai Lifesciences Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 207.89 $ 203.84 $ 184.99 $ 191.31 $ 215.85
Y / Y Revenue Growth (TTM) -3.69 % -15.72 % -28.63 % -30.92 % -22.52 %
Year on Year Revenue Growth Overall Ranking # 3262 # 2125 # 1957 # 3266 # 3200
Seqeuential Revenue Change (TTM) 1.98 % 10.19 % -3.3 % -11.37 % -10.75 %
Seq. Revenue Growth (TTM) Overall Ranking # 3051 # 2578 # 2533 # 2313 # 2241


Cumulative Revenue growth Comment
Maravai Lifesciences Holdings Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Maravai Lifesciences Holdings Inc 's annual Revenue decrease would be -3.69% year on year to $208 millions.

In the Healthcare sector 445 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2125 to 3262.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 446
Overall # 3262

Revenue TTM Y/Y Growth Statistics
High Average Low
10.48 %
 -31.16 %
-68.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 412
S&P 500 # 3051
Cumulative Revenue growth Comment
Maravai Lifesciences Holdings Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Maravai Lifesciences Holdings Inc 's annual Revenue drop would be -3.69% year on year to $208 millions.

In the Healthcare sector 445 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2125 to 3262.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 446
Overall # 3262

Revenue TTM Y/Y Growth Statistics
High Average Low
10.48 %
-31.16 %
-68.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 412
S&P 500 # 3051




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRVI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions


About Maravai Lifesciences Holdings Inc Revenue Growth Rates (MRVI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Maravai Lifesciences Holdings Inc (CIK 1823239).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001823239-26-000059
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Maravai Lifesciences Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.